Different Units By MoH Code
Revision Date : 11/01/2013
NovoSeven RT 50KIU MoH 5540 :
| Form |
Powder and solvent for solution for injection |
| Packaging |
Pre-filled Syringes + Vials (Type I glass) |
| Package Size |
1+1 |
| Strength |
1mg (50KIU) |
| Public Price |
60203801.93 L.L. |
| Stratum |
E1 |
| NSSF |
✔ |
| Quarantine |
✔ |
| Reg. Number |
218019/09 |
| Submission date |
01/01/2009 |
| Registration Year |
2009 |
|
●
Country:
|
Italy
|
|
●
Package Size:
|
1+1x1.1ml
|
|
●
Public Price:
|
1079.12 EUR
|
( 104,540,829.12 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
1079,12 EUR
|
( 104,529,204.00 LBP )
|
|
●
Exfactory Price:
|
653.85 EUR
|
|
●
Pricing Date:
|
17/12/2019
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Qatar
|
|
●
Package Size:
|
1 powder vial + 1 Solvent pre-filled syringe + vial adapter
|
|
●
Public Price:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
●
Pharmacy Price:
|
3255.49386266 QAR
|
( 79948418.279204 LBP )
|
|
●
Pricing Date:
|
28/01/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Oman
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
417.29 OMR
|
( 96,282,990.86 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
417,29 OMR
|
( 96,216,078.00 LBP )
|
|
●
Pricing Date:
|
19/02/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Switzerland
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
907.55 CHF
|
( 93,858,821.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
907,55 CHF
|
( 93,801,940.00 LBP )
|
|
●
Exfactory Price:
|
845.41 CHF
|
|
●
Pricing Date:
|
04/04/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Kuweit
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
319.2 KWD
|
( 93,711,055.20 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
319,2 KWD
|
( 93,652,339.00 LBP )
|
|
●
Pharmacy Price:
|
269.67 KWD
|
( 79169988.27 LBP )
|
|
●
Pricing Date:
|
07/02/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Germany
|
|
●
Package Size:
|
1
|
|
●
Public Price:
|
927.81 EUR
|
( 89,882,521.56 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
927,81 EUR
|
( 89,804,052.00 LBP )
|
|
●
Pricing Date:
|
24/10/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Abu Dhabi
|
|
●
Package Size:
|
1+1x1.1ml
|
|
●
Public Price:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
●
Pharmacy Price:
|
3154.78 AED
|
( 76222639.58 LBP )
|
|
●
Pricing Date:
|
27/01/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
UAE
|
|
●
Package Size:
|
1 Vial (Powder) + 1 Solvent Vial (1.1ml)
|
|
●
Public Price:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
●
Pharmacy Price:
|
3154.78 AED
|
( 76222639.58 LBP )
|
|
●
Pricing Date:
|
21/08/2019
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Bahrain
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
352.25 BHD
|
( 83,741,801.50 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
352,25 BHD
|
( 83,682,368.00 LBP )
|
|
●
Reference:
|
nhra
|
|
●
Pricing Date:
|
09/02/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Finland
|
|
●
Package Size:
|
1+1x1ml
|
|
●
Public Price:
|
809.89 EUR
|
( 78,458,903.64 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
809,89 EUR
|
( 78,372,684.00 LBP )
|
|
●
Reference:
|
Kela
|
|
●
Pricing Date:
|
22/04/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Iceland
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
●
Pharmacy Price:
|
84672 ISK
|
( 54613440 LBP )
|
|
●
Reference:
|
Icelandic Medicines Agency
|
|
●
Pricing Date:
|
01/04/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Denmark
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
5318.1 DKK
|
( 69,007,665.60 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
5318,1 DKK
|
( 69,006,368.00 LBP )
|
|
●
Pharmacy Price:
|
3948.91 DKK
|
( 51241056.16 LBP )
|
|
●
Reference:
|
Danish Medicine Agency
|
|
●
Pricing Date:
|
19/05/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Czech Republic
|
|
●
Package Size:
|
1+1x1ml
|
|
●
Public Price:
|
17583.04 CZK
|
( 67,149,629.76 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
17583,04 CZK
|
( 67,149,477.00 LBP )
|
|
●
Reference:
|
SUKL
|
|
●
Pricing Date:
|
28/02/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
KSA
|
|
●
Package Size:
|
1mg
|
|
●
Public Price:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
●
Reference:
|
sfda
|
|
●
Pricing Date:
|
16/01/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Greece
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
642.66 EUR
|
( 62,258,330.16 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
642,66 EUR
|
( 62,194,392.00 LBP )
|
|
●
Reference:
|
National Organization for Medicines
|
|
●
Pricing Date:
|
25/03/2019
|
|
●
Type:
|
Medicine Non Marketed
|
|
●
Country:
|
Spain
|
|
●
Package Size:
|
1 vial + 1xdisolvente
|
|
●
Public Price:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
●
Reference:
|
Agencia Española de Medicamentos y Productos Sanitarios
|
|
●
Pricing Date:
|
06/05/2021
|
|
●
Type:
|
Medicine Non Marketed
|
|
●
Country:
|
Lebanon
|
|
●
Form:
|
Powder and solvent for solution for injection
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
60203801.93 LBP
|
( 60,203,801.93 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
60203801,93 LBP
|
( 60,203,801.00 LBP )
|
|
●
Pricing Date:
|
03/09/2026
|
|
●
Country:
|
UK
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
525.2 GBP
|
( 59,688,454.80 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
525,2 GBP
|
( 59,665,725.00 LBP )
|
|
●
Reference:
|
DMD
|
|
●
Pricing Date:
|
08/03/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
France
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
●
Reference:
|
ansm
|
|
●
Pricing Date:
|
15/05/2021
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Belgium
|
|
●
Package Size:
|
1+1x1.1ml
|
|
●
Public Price:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
●
Reference:
|
cbip
|
|
●
Pricing Date:
|
02/12/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Norway
|
|
●
Package Size:
|
1
|
|
●
Public Price:
|
6048.4 NOK
|
( 49,016,233.60 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
6048,4 NOK
|
( 49,012,992.00 LBP )
|
|
●
Pharmacy Price:
|
4715.41 NOK
|
( 38213682.64 LBP )
|
|
●
Reference:
|
Norwegian Medicine Agency
|
|
●
Pricing Date:
|
01/04/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Sweden
|
|
●
Package Size:
|
1+1
|
|
●
Public Price:
|
5733.56 SEK
|
( 48,207,772.48 LBP )
|
|
●
Pack size unit used:
|
1
|
|
●
Cost/Unit:
|
5733,56 SEK
|
( 48,203,064.00 LBP )
|
|
●
Pharmacy Price:
|
5575.79 SEK
|
( 46881242.32 LBP )
|
|
●
Pricing Date:
|
23/04/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
Portugal
|
|
●
Package Size:
|
1+1
|
|
●
Reference:
|
Autoridade Nacional do Medicamento e Produtos de Saúde
|
|
●
Pricing Date:
|
22/04/2019
|
|
●
Country:
|
New Zealand
|
|
●
Package Size:
|
1 inj
|
|
●
Exfactory Price:
|
1178.3 NZD
|
|
●
Reference:
|
New Zealand Pharmaceutical Management Agency
|
|
●
Pricing Date:
|
01/04/2020
|
|
●
Type:
|
Medicine Authorised
|
|
●
Country:
|
The Netherlands
|
|
●
Package Size:
|
1
|
|
●
Reference:
|
Zorginstituut Nederland
|
|
●
Pricing Date:
|
15/06/2019
|
|
●
Type:
|
Medicine Non Marketed
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
1079,12 EUR
|
( 104,529,204.00 LBP )
|
|
● Cost/Day:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
|
●
Cost/Month:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
1079,12 EUR
|
( 104,529,204.00 LBP )
|
|
● Cost/Day:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
|
●
Cost/Month:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
1079,12 EUR
|
( 104,529,204.00 LBP )
|
|
● Cost/Day:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
|
●
Cost/Month:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
1079,12 EUR
|
( 104,529,204.00 LBP )
|
|
● Cost/Day:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
|
●
Cost/Month:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
1079,12 EUR
|
( 104,529,204.00 LBP )
|
|
● Cost/Day:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
|
●
Cost/Month:
|
6474,72 EUR
|
( 627,175,224.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
● Cost/Day:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
|
●
Cost/Month:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
● Cost/Day:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
|
●
Cost/Month:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
● Cost/Day:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
|
●
Cost/Month:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
● Cost/Day:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
|
●
Cost/Month:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
3963 QAR
|
( 97,323,354.00 LBP )
|
|
● Cost/Day:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
|
●
Cost/Month:
|
23778 QAR
|
( 583,940,124.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
417,29 OMR
|
( 96,216,078.00 LBP )
|
|
● Cost/Day:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
|
●
Cost/Month:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
417,29 OMR
|
( 96,216,078.00 LBP )
|
|
● Cost/Day:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
|
●
Cost/Month:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
417,29 OMR
|
( 96,216,078.00 LBP )
|
|
● Cost/Day:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
|
●
Cost/Month:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
417,29 OMR
|
( 96,216,078.00 LBP )
|
|
● Cost/Day:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
|
●
Cost/Month:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
417,29 OMR
|
( 96,216,078.00 LBP )
|
|
● Cost/Day:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
|
●
Cost/Month:
|
2503,74 OMR
|
( 577,527,202.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
907,55 CHF
|
( 93,801,940.00 LBP )
|
|
● Cost/Day:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
|
●
Cost/Month:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
907,55 CHF
|
( 93,801,940.00 LBP )
|
|
● Cost/Day:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
|
●
Cost/Month:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
907,55 CHF
|
( 93,801,940.00 LBP )
|
|
● Cost/Day:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
|
●
Cost/Month:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
907,55 CHF
|
( 93,801,940.00 LBP )
|
|
● Cost/Day:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
|
●
Cost/Month:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
907,55 CHF
|
( 93,801,940.00 LBP )
|
|
● Cost/Day:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
|
●
Cost/Month:
|
5445,3 CHF
|
( 563,121,900.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
319,2 KWD
|
( 93,652,339.00 LBP )
|
|
● Cost/Day:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
|
●
Cost/Month:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
319,2 KWD
|
( 93,652,339.00 LBP )
|
|
● Cost/Day:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
|
●
Cost/Month:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
319,2 KWD
|
( 93,652,339.00 LBP )
|
|
● Cost/Day:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
|
●
Cost/Month:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
319,2 KWD
|
( 93,652,339.00 LBP )
|
|
● Cost/Day:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
|
●
Cost/Month:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
319,2 KWD
|
( 93,652,339.00 LBP )
|
|
● Cost/Day:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
|
●
Cost/Month:
|
1915,2 KWD
|
( 562,207,615.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
927,81 EUR
|
( 89,804,052.00 LBP )
|
|
● Cost/Day:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
|
●
Cost/Month:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
927,81 EUR
|
( 89,804,052.00 LBP )
|
|
● Cost/Day:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
|
●
Cost/Month:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
927,81 EUR
|
( 89,804,052.00 LBP )
|
|
● Cost/Day:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
|
●
Cost/Month:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
927,81 EUR
|
( 89,804,052.00 LBP )
|
|
● Cost/Day:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
|
●
Cost/Month:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
927,81 EUR
|
( 89,804,052.00 LBP )
|
|
● Cost/Day:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
|
●
Cost/Month:
|
5566,86 EUR
|
( 539,211,816.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
3703 AED
|
( 89,468,183.00 LBP )
|
|
● Cost/Day:
|
22218 AED
|
( 536,809,098.00 LBP )
|
|
●
Cost/Month:
|
22218 AED
|
( 536,809,098.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
352,25 BHD
|
( 83,682,368.00 LBP )
|
|
● Cost/Day:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
|
●
Cost/Month:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
352,25 BHD
|
( 83,682,368.00 LBP )
|
|
● Cost/Day:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
|
●
Cost/Month:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
352,25 BHD
|
( 83,682,368.00 LBP )
|
|
● Cost/Day:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
|
●
Cost/Month:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
352,25 BHD
|
( 83,682,368.00 LBP )
|
|
● Cost/Day:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
|
●
Cost/Month:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
352,25 BHD
|
( 83,682,368.00 LBP )
|
|
● Cost/Day:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
|
●
Cost/Month:
|
2113,5 BHD
|
( 502,331,942.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
809,89 EUR
|
( 78,372,684.00 LBP )
|
|
● Cost/Day:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
|
●
Cost/Month:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
809,89 EUR
|
( 78,372,684.00 LBP )
|
|
● Cost/Day:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
|
●
Cost/Month:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
809,89 EUR
|
( 78,372,684.00 LBP )
|
|
● Cost/Day:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
|
●
Cost/Month:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
809,89 EUR
|
( 78,372,684.00 LBP )
|
|
● Cost/Day:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
|
●
Cost/Month:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
809,89 EUR
|
( 78,372,684.00 LBP )
|
|
● Cost/Day:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
|
●
Cost/Month:
|
4859,34 EUR
|
( 470,720,484.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
● Cost/Day:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
|
●
Cost/Month:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
● Cost/Day:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
|
●
Cost/Month:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
● Cost/Day:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
|
●
Cost/Month:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
● Cost/Day:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
|
●
Cost/Month:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
110287 ISK
|
( 71,135,115.00 LBP )
|
|
● Cost/Day:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
|
●
Cost/Month:
|
661722 ISK
|
( 426,810,690.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
5318,1 DKK
|
( 69,006,368.00 LBP )
|
|
● Cost/Day:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
|
●
Cost/Month:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
5318,1 DKK
|
( 69,006,368.00 LBP )
|
|
● Cost/Day:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
|
●
Cost/Month:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
5318,1 DKK
|
( 69,006,368.00 LBP )
|
|
● Cost/Day:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
|
●
Cost/Month:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
5318,1 DKK
|
( 69,006,368.00 LBP )
|
|
● Cost/Day:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
|
●
Cost/Month:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
5318,1 DKK
|
( 69,006,368.00 LBP )
|
|
● Cost/Day:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
|
●
Cost/Month:
|
31908,6 DKK
|
( 414,038,208.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
17583,04 CZK
|
( 67,149,477.00 LBP )
|
|
● Cost/Day:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
|
●
Cost/Month:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
17583,04 CZK
|
( 67,149,477.00 LBP )
|
|
● Cost/Day:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
|
●
Cost/Month:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
17583,04 CZK
|
( 67,149,477.00 LBP )
|
|
● Cost/Day:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
|
●
Cost/Month:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
17583,04 CZK
|
( 67,149,477.00 LBP )
|
|
● Cost/Day:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
|
●
Cost/Month:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
17583,04 CZK
|
( 67,149,477.00 LBP )
|
|
● Cost/Day:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
|
●
Cost/Month:
|
105498,24 CZK
|
( 402,896,862.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
● Cost/Day:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
|
●
Cost/Month:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
● Cost/Day:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
|
●
Cost/Month:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
● Cost/Day:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
|
●
Cost/Month:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
● Cost/Day:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
|
●
Cost/Month:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
2640 SAR
|
( 62,409,600.00 LBP )
|
|
● Cost/Day:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
|
●
Cost/Month:
|
15840 SAR
|
( 374,457,600.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
642,66 EUR
|
( 62,194,392.00 LBP )
|
|
● Cost/Day:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
|
●
Cost/Month:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
642,66 EUR
|
( 62,194,392.00 LBP )
|
|
● Cost/Day:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
|
●
Cost/Month:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
642,66 EUR
|
( 62,194,392.00 LBP )
|
|
● Cost/Day:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
|
●
Cost/Month:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
642,66 EUR
|
( 62,194,392.00 LBP )
|
|
● Cost/Day:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
|
●
Cost/Month:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
642,66 EUR
|
( 62,194,392.00 LBP )
|
|
● Cost/Day:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
|
●
Cost/Month:
|
3855,96 EUR
|
( 373,456,980.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
● Cost/Day:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
|
●
Cost/Month:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
● Cost/Day:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
|
●
Cost/Month:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
● Cost/Day:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
|
●
Cost/Month:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
● Cost/Day:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
|
●
Cost/Month:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
639 EUR
|
( 61,903,764.00 LBP )
|
|
● Cost/Day:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
|
●
Cost/Month:
|
3834 EUR
|
( 371,422,584.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
60203801,93 LBP
|
( 60,203,801.00 LBP )
|
|
● Cost/Day:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
|
●
Cost/Month:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
60203801,93 LBP
|
( 60,203,801.00 LBP )
|
|
● Cost/Day:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
|
●
Cost/Month:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
60203801,93 LBP
|
( 60,203,801.00 LBP )
|
|
● Cost/Day:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
|
●
Cost/Month:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
60203801,93 LBP
|
( 60,203,801.00 LBP )
|
|
● Cost/Day:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
|
●
Cost/Month:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
60203801,93 LBP
|
( 60,203,801.00 LBP )
|
|
● Cost/Day:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
|
●
Cost/Month:
|
361222811,58 LBP
|
( 361,222,811.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
525,2 GBP
|
( 59,665,725.00 LBP )
|
|
● Cost/Day:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
|
●
Cost/Month:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
525,2 GBP
|
( 59,665,725.00 LBP )
|
|
● Cost/Day:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
|
●
Cost/Month:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
525,2 GBP
|
( 59,665,725.00 LBP )
|
|
● Cost/Day:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
|
●
Cost/Month:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
525,2 GBP
|
( 59,665,725.00 LBP )
|
|
● Cost/Day:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
|
●
Cost/Month:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
525,2 GBP
|
( 59,665,725.00 LBP )
|
|
● Cost/Day:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
|
●
Cost/Month:
|
3151,2 GBP
|
( 358,107,999.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
● Cost/Day:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
|
●
Cost/Month:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
● Cost/Day:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
|
●
Cost/Month:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
● Cost/Day:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
|
●
Cost/Month:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
● Cost/Day:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
|
●
Cost/Month:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
608 EUR
|
( 58,900,608.00 LBP )
|
|
● Cost/Day:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
|
●
Cost/Month:
|
3648 EUR
|
( 353,403,648.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
● Cost/Day:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
|
●
Cost/Month:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
● Cost/Day:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
|
●
Cost/Month:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
● Cost/Day:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
|
●
Cost/Month:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
● Cost/Day:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
|
●
Cost/Month:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
532 EUR
|
( 51,538,032.00 LBP )
|
|
● Cost/Day:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
|
●
Cost/Month:
|
3192 EUR
|
( 309,228,192.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
6048,4 NOK
|
( 49,012,992.00 LBP )
|
|
● Cost/Day:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
|
●
Cost/Month:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
6048,4 NOK
|
( 49,012,992.00 LBP )
|
|
● Cost/Day:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
|
●
Cost/Month:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
6048,4 NOK
|
( 49,012,992.00 LBP )
|
|
● Cost/Day:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
|
●
Cost/Month:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
6048,4 NOK
|
( 49,012,992.00 LBP )
|
|
● Cost/Day:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
|
●
Cost/Month:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
6048,4 NOK
|
( 49,012,992.00 LBP )
|
|
● Cost/Day:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
|
●
Cost/Month:
|
36290,4 NOK
|
( 294,094,160.00 LBP )
|
Acquired haemophilia :
(Adults)
|
●
Cost/Unit:
|
5733,56 SEK
|
( 48,203,064.00 LBP )
|
|
● Cost/Day:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
|
●
Cost/Month:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
Congenital FVII deficiency :
(Adults)
|
●
Cost/Unit:
|
5733,56 SEK
|
( 48,203,064.00 LBP )
|
|
● Cost/Day:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
|
●
Cost/Month:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors IX :
(Adults)
|
●
Cost/Unit:
|
5733,56 SEK
|
( 48,203,064.00 LBP )
|
|
● Cost/Day:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
|
●
Cost/Month:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
Congenital haemophilia with inhibitors to coagulation factors VIII :
(Adults)
|
●
Cost/Unit:
|
5733,56 SEK
|
( 48,203,064.00 LBP )
|
|
● Cost/Day:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
|
●
Cost/Month:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
Glanzmann’s thrombasthenia with antibodies to GP IIb - IIIa and/or HLA :
(Adults)
|
●
Cost/Unit:
|
5733,56 SEK
|
( 48,203,064.00 LBP )
|
|
● Cost/Day:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
|
●
Cost/Month:
|
34401,36 SEK
|
( 289,243,608.00 LBP )
|
Prices are provided in Dollar ($)
You have to register to view this info
You have to register to view this info
